Venetoclax, a BCL-2 inhibitor, has shown promise in treating multiple myeloma, particularly in patients with the t(11;14) translocation. However, response rates vary, prompting researchers to investigate genomic determinants of clinical outcomes in this subgroup. A recent study presented at the 2024 ASH Annual Meeting, led by Dr. Marcella Ali Kaddoura from the University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Center, delved into the genomic profiles of patients with t(11;14)-positive multiple myeloma harboring IGH/CCND1 rearrangements who were treated with venetoclax.
The research focused on identifying specific genomic features that correlate with response to venetoclax. The study included patients with relapsed or refractory multiple myeloma who had received venetoclax-based therapies. Genomic data, including cytogenetic abnormalities and gene mutations, were analyzed to determine their association with clinical outcomes such as progression-free survival (PFS) and overall response rate (ORR).
Key Findings
The investigation revealed that certain genomic aberrations were associated with differential responses to venetoclax. While specific details on these aberrations were not elaborated in the source material, the study suggests that a comprehensive genomic assessment could help predict which patients with t(11;14) myeloma are most likely to benefit from venetoclax treatment. This is particularly important as venetoclax is not universally effective in this patient population.
Clinical Implications
These findings have significant implications for the treatment of multiple myeloma. By identifying genomic predictors of venetoclax response, clinicians can potentially personalize treatment strategies, avoiding unnecessary exposure to the drug in patients unlikely to respond and prioritizing it for those with a higher likelihood of benefit. Further research is needed to validate these findings in larger cohorts and to develop clinically applicable genomic biomarkers. The study underscores the importance of genomic profiling in guiding treatment decisions and improving outcomes for patients with t(11;14)-positive multiple myeloma.
